X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 58 filers reported holding X4 PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $54 | -91.3% | 93,821 | -79.1% | 0.00% | – |
| Q1 2024 | $623 | +40.6% | 448,708 | -15.3% | 0.00% | – |
| Q4 2023 | $443 | +6.2% | 529,601 | +38.6% | 0.00% | – |
| Q3 2023 | $417 | +145.3% | 382,134 | +334.8% | 0.00% | – |
| Q2 2023 | $170 | – | 87,879 | +87779.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 100 | -98.7% | 0.00% | – |
| Q1 2022 | $14,000 | -61.1% | 7,804 | -50.0% | 0.00% | – |
| Q4 2021 | $36,000 | -30.8% | 15,608 | +57.7% | 0.00% | – |
| Q3 2021 | $52,000 | -51.4% | 9,899 | -39.7% | 0.00% | – |
| Q2 2021 | $107,000 | -41.5% | 16,410 | -22.8% | 0.00% | – |
| Q1 2021 | $183,000 | +120.5% | 21,245 | +63.5% | 0.00% | – |
| Q4 2020 | $83,000 | +8200.0% | 12,993 | +9180.7% | 0.00% | – |
| Q2 2020 | $1,000 | -99.5% | 140 | -99.2% | 0.00% | – |
| Q4 2019 | $188,000 | +154.1% | 17,563 | +200.1% | 0.00% | – |
| Q3 2019 | $74,000 | +1750.0% | 5,852 | +2288.6% | 0.00% | – |
| Q1 2019 | $4,000 | – | 245 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 1,578,947 | $3,616,000 | 1.42% |
| AIGH Capital Management LLC | 1,464,099 | $3,353,000 | 1.02% |
| Ikarian Capital, LLC | 2,264,491 | $5,186,000 | 0.77% |
| Bain Capital Life Sciences Investors, LLC | 2,886,542 | $6,610,000 | 0.52% |
| SV Health Investors, LLC | 311,490 | $713,000 | 0.46% |
| Worth Venture Partners, LLC | 340,495 | $780,000 | 0.39% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $767,000 | 0.28% |
| Sio Capital Management, LLC | 276,909 | $634,000 | 0.19% |
| BVF INC/IL | 847,879 | $1,942,000 | 0.07% |
| Orbimed Advisors | 1,373,849 | $3,146,000 | 0.04% |